scispace - formally typeset
J

Jean-Jacques Body

Researcher at Université libre de Bruxelles

Publications -  397
Citations -  21506

Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

Targeting bone metastases in prostate cancer: improving clinical outcome

Jean-Jacques Body, +2 more
- 01 Jun 2015 - 
TL;DR: Radium-223 dichloride is the first bone-targeting agent to show improved survival and reduced pain and symptomatic skeletal events in patients with mCRPC without visceral disease, suggesting that managing both the systemic disease and associated bone events is important.
Journal ArticleDOI

Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

René Rizzoli, +5 more
- 20 Jan 2012 - 
TL;DR: Aromatase inhibitors are widely used in women with breast cancer, but they are known to increase bone loss and risk of fractures, so an ESCEO working group recommends that all AI-treated women should be evaluated for fracture risk.
Journal ArticleDOI

Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride

Hubertus I.J. Harinck, +7 more
- 01 Jun 1987 - 
TL;DR: It is demonstrated that increased bone resorption is the major contributory factor and that inhibition with bisphosphonate normalizes the serum calcium concentration within five days in more than 90 percent of patients.
Journal ArticleDOI

2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study

A. Stopeck, +9 more
- 01 Sep 2009 - 
Journal ArticleDOI

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

Roger von Moos, +13 more
- 22 Aug 2013 - 
TL;DR: Across three large studies of patients with advanced solid tumours and bone metastases, denosumab prevented progression of pain severity and pain interference more effectively than zoledronic acid.